This is the authors' abstract. We don't add key points for this paper.
Gastroesophageal reflux disease (GERD), including nonerosive reflux disease (NERD) and reflux esophagitis, is defined as the presence of reflux-associated symptoms and/or esophageal mucosal damage caused by the reflux of gastric content into the esophagus.1 In general, the main therapeutic strategy for GERD is potent acid inhibition for a 24 h period. This is because esophageal mucosal breaks and reflux-related symptoms are closely related to not only intraesophageal and intragastric pH values but also to the number of episodes of reflux and to reflux duration. Cure rates with acid inhibition are generally influenced by a number of factors, including CYP2C19 genotype in treatment with proton pump inhibitors (PPIs), vonoprazan/PPI dose, presence of functional heartburn and reflux hypersensitivity, Helicobacter pylori infection, sliding hernia, eosinophilic esophagitis and major motility disorders (achalasia, esophagogastric junction outflow obstruction, distal esophageal spasm, jackhammer esophagus, and absent contractility).2 Of GERD-related diseases refractory to acid inhibition, reflux hypersensitivity is defined as retrosternal symptoms, including heartburn or chest pain triggered by physiological reflux in the absence of abnormally increased gastroesophageal reflux on pH or ambulatory pH-impedance monitoring, and functional heartburn is defined as retrosternal burning discomfort or pain refractory to potent acid inhibition in the absence of GERD.1 Recently, these diseases have been increasing among GERD patients in Japan, and it is considered important to take measures to cure them. Although response to potent acid inhibition by PPI/vonoprazan does not exclude diagnosis of reflux hypersensitivity, most reflux hypersensitivity is refractory to PPI/vonoprazan therapy, and reflux hypersensitivity related to bile acid reflux to the esophagus has been the focus of much recent attention. The prevalence of bile acid reflux among all GERD patients ranges from 10% to 97%, in NERD 10–63%, in erosive esophagitis 22–80%, and in Barrett's esophagus 50–100%.3 Although bile acid reflux is most commonly caused by surgery (e.g., gastric surgery, gallbladder removal surgery), esophageal mucosal inflammation and tissue damage also often result from sliding hernia, impaired gastrointestinal motility and kyphosis, and chronic and frequent bile acid reflux. In ex vivo/in vitro studies, bile acids including cholic acid, chenodeoxycholic acid, and deoxycholic acid stimulate squamous cells and Barrett's epithelium cells, resulting in the infiltration of activated inflammatory cells and the increase of proinflammatory cytokines (e.g., interleukin [IL]-6, IL-8) and inflammation-related mediators (e.g., prostaglandin E2, cyclo-oxygenase-2) into the esophageal mucosa.4 In fact, esophageal refluxates in patients with GERD and Barrett's epithelium cells show high concentrations of deoxycholic acid in the clinical setting. Additionally, conjugated bile acid levels in the refluxate from patients with advanced esophageal adenocarcinoma are significantly higher than from patients with Barrett's epithelium cells without cancer. In relation with these enhanced chronic mucosal inflammation and direct reaction of bile acids to esophageal mucosa, these bile acids, which have cytotoxic effects in different cell types, are considered to cause oxidative stress (e.g., increase of reactive oxygen species, including nitric oxide), DNA damage, and apoptosis, and finally relate with esophageal carcinogenesis. Increased DNA damage administrated by bile acid confirmed by the Comet assay or the DNA ladder extraction was evident in both normal squamous cells and squamous carcinoma lines.4 Bile acids induce squamous cells to change gene expression patterns, such as positive for CDX2 (a gene known to play a key role in the development of intestinal epithelia), bone morphogenetic protein-4 (a member of transforming growth factor-β family that might promote squamous-to-columnar metaplasia), and mucin 2 (a mucin normally found in intestinal goblet cells, to resemble intestinal-type cells including Barrett's epithelium). And, not only these change but also continuous direct stimulation by bile acids to esophageal mucosa may cause carcinogenesis for Barrett's adenocarcinoma and squamous cell carcinoma.4 Therefore, it is extremely important to accurately assess not only acid reflux but also bile acid reflux, and to develop countermeasures in clinical settings for patients with GERD. Bile acid reflux is generally diagnosed by endoscopy, hepatobiliary iminodiacetic acid scanning (a radiographic imaging test), the Bilitec monitoring system (a photo-colorimetric device, Bilitec 2000; Medtronic Functional Diagnostics Inc, Minneapolis, Minnesota, USA), and esophageal impedance testing (to measure whether the content is acidic or nonacidic). Nevertheless, no conventional system that accurately measures bile acid reflux to the esophagus has been established. Regarding the endoscopic method of image-enhanced endoscopy to evaluate bile in the gastrointestinal tract, an endoscopy system with blue laser imaging (BLI) (blue-violet light, 410 nm) or narrow-band imaging modes (415 and 540 nm) is reportedly useful in visualizing bile juice regardless of gastrointestinal location.5 In contrast, because of advances in optical technology, recent results show that narrow-band light of 450 and 473 nm wavelengths can detect bilirubin in bile juice (EP-0002 system; Fujifilm Co., Ltd, Tokyo, Japan).6 Substances with absorbance properties similar to that of bilirubin can be displayed as red in color mapping images by setting the absorbance of deoxyhemoglobin at 450 and 473 nm as references. This EP-0002 system may therefore be expected to evaluate status of bile acid in gastrointestinal tract. In this issue of Digestive Endoscopy, although Wada et al.7 did not develop the EP-0002 system, they first reported that when the image enhancement mode for detecting bilirubin (Bil mode, EP-0002 system) was used, bilirubin solutions with bile concentrations higher than 1% were visualized in red in an in vitro study, and that the Bil mode had efficacy in evaluating 1–6% bilirubin solutions compared with BLI and white light imaging (WLI) in an ex vivo study. Among bile juice, pancreatic juice, gastric juice, dimethicone, pronase, iodixanol, and distilled water, only bile juice was visualized in red. This EP-0002 system therefore appears sufficiently sensitive for assessing bile acid status in the gastrointestinal tract. These results demonstrate that this method has excellent detection ability when compared with WLI and other image-enhanced endoscopy procedures for solutions containing bilirubin at concentrations as low as 1%. In addition, as a clinical trial, the authors showed significant differences in bilirubin values among esophagus, stomach, and duodenum, and demonstrated a significant positive correlation between the number of nonacid reflux events during multichannel intraluminal impedance-pH monitoring and calculated values of bilirubin (P = 0.031). The authors demonstrated for the first time that the Bil mode of the EP-0002 system was useful for bilirubin (bile acid reflux) detection in bile juice not just in in vitro study, but also in in vivo study. This study's demonstration that bile acid reflux into the esophagus can be easily assessed by a new endoscopic EP-0002 system operating over narrow-band lighting at wavelengths of 450 and 473 nm offers substantial benefit to the clinical treatment of GERD. Compared with other endoscopic detection systems (e.g., WLI, BLI), the detection performance of the EP-0002 system for bilirubin shows efficacy at concentrations between 1% and 6% of undiluted bile juice, giving it an advantage in clinical practice. In general, the bilirubin concentration of gastric juice is 1.28 ± 0.25 mg/dL, which corresponds to 2.5–7.6% of the general bilirubin concentration in bile juice.8 To date, however, no study has measured bilirubin concentration in the esophagus in a large-scale clinical trial. Because bilirubin level is considered lower in the esophagus than in gastric juice, its re-evaluation in a large-scale clinical trial is considered necessary. It is anticipated that bile acid reflux can be easily evaluated using the EP-0002 system and that patients with bile acid reflux will be appropriately diagnosed from the population of patients with GERD. The next question is the importance of evaluating bile acid reflux in clinical practice. In this study, the area under the curve for the differential diagnosis of reflux hypersensitivity was 0.817, making the EP-0002 system with Bil mode useful for the differential diagnosis of reflux hypersensitivity.7 Tack et al.9 reported that 38% of PPI-refractory GERD is attributable to bile acid reflux without acid exposure and that bile acid reflux is observed in approximately 60% of patients with reflux hypersensitivity. The differential diagnosis of GERD from bile acid reflux-related reflux hypersensitivity is an important issue in which, although there are no studies comparing VPZ and PPI tests regarding the diagnostic ability of GERD, the vonoprazan test with potent acid inhibition may be of use.10 If bile acid reflux is observed using the EP-0002 system in endoscopy to closely examine reflux-related symptoms, is there an option not to use acid secretion inhibitors? Although physician providers prescribe a variety of medications (e.g., ursodeoxycholic acid, prokinetic agents, sucralfate, baclofen) to treat bile acid reflux and related abdominal symptoms, no conclusive treatment has yet been established. In fact, there are no randomized control trials to compare several medications or surgical treatments. The reports of observational trials included nine studies evaluating PPIs, two evaluating prokinetics (cisapride, 5HT4 receptor agonist), one evaluating surgical treatment (a Nissen fundoplication), one evaluating histamine receptor antagonists, and one evaluating baclofen (a GABAB agonist, 5–20 mg three times daily).3 However, the reduction of bile acid reflux parameters on PPI may represent an epiphenomenon unrelated to symptom improvement. In this study, the authors recommend using the EP-0002 system to evaluate bile acid reflux involvement in patients with vonoprazan/PPI-refractory GERD symptoms. However, if endoscopic evaluation is performed prior to pharmacological therapy for reflux-related symptoms, this mode can be easily switched on by pressing a button, and evaluation at that time may be considered necessary. Given that many clinical questions about bile acid reflux in the clinical treatment of GERD remain unanswered, the establishment of an endoscopic system that can improve the rate of correct diagnosis is highly significant. Important jobs for the future include identifying the most effective ways to use the EP-0002 system, research on when and how bile acid reflux is diagnosed, and use in evaluating the effectiveness of medical treatment. Given that many clinical questions about bile acid reflux in the clinical treatment of GERD remain unanswered, the establishment of an endoscopic system that can improve the rate of correct diagnosis is highly significant. Important jobs for the future include identifying the most effective ways to use the EP-0002 system, research on when and how bile acid reflux is diagnosed, and use in evaluating the effectiveness of medical treatment. Authors declare no conflict of interest for this article. None.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Sugimoto et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: